02/01/23 8:00 AMNasdaq : SONN low floatSonnet BioTherapeutics Announces Successful Completion of Two IND-Enabling Toxicology Studies with SON-1210 in Non-Human PrimatesSON-1210 elicited no serious adverse events in repeat, subcutaneous dosing in a GLP toxicology study SON-1210 was well-tolerated using dosing levels at least 50x higher than the highest anticipated human clinical dose level Data show controlled induction of IFNg with no signs of cytokine releaseRHEA-AIneutral
01/19/23 8:00 AMNasdaq : SONN clinical triallow floatSonnet BioTherapeutics Announces Pharmacokinetic and Pharmacodynamic Data in a Phase 1 Dose-Escalation Trial of SON-101024 healthy volunteers have been dosed in study SB102 to assess the safety, PK, and PD of SON-1010 without the background of prior chemotherapy PK data shows an extended half-life of SON-1010 of approximately 112 hours, compared to 12 hours for rhIL-12 Simulation of the controlled and prolongedRHEA-AIneutral
01/09/23 8:00 AMNasdaq : SONN low floatSonnet BioTherapeutics Announces a Collaboration with Roche for the Clinical Evaluation of SON-1010 with atezolizumab in Ovarian CancerSonnet's lead product, SON-1010, to be evaluated in combination with Roche's atezolizumab (Tecentriq ®) Sonnet will sponsor the clinical study in patients with platinum-resistant ovarian cancer, scheduled to commence during the second calendar quarter of 2023, and Roche will supply atezolizumabRHEA-AIpositive
12/15/22 4:05 PMNasdaq : SONN earningslow floatSonnet BioTherapeutics Provides Fiscal Year 2022 Business and Financial UpdateSonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the fiscal year ended September 30 th, 2022 andRHEA-AIpositive
11/02/22 8:00 AMNasdaq : SONN clinical triallow floatSonnet BioTherapeutics Announces Interim Data in Two Phase 1 Dose-Escalation Trials of SON-1010The SB101 and SB102 studies have together dosed 36 subjects to date as dose escalation continues Cytokine data show extended pharmacokinetics of SON-1010 with controlled induction of IFNγ and no signs of cytokine release syndrome All but one patient remain on study, with evidence of tumorRHEA-AIneutral
11/01/22 4:05 PMNasdaq : SONN clinical triallow floatSonnet BioTherapeutics Announces Webcast to Discuss Interim Data from the Company’s Phase 1 Dose-Escalation Trials of SON-1010 on November 2, 2022Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the company will host a webcast to share initial clinical data from its SB101 clinical study with SON-1010RHEA-AIneutral
10/31/22 7:30 AMNasdaq : SONN low floatSonnet BioTherapeutics Announces an Agreement with Janssen for the Evaluation of Three Sonnet Product CandidatesRHEA-AIvery positive
10/04/22 8:00 AMNasdaq : SONN low floatSonnet BioTherapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementSonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet BioTherapeutics"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that it received notice from The Nasdaq Stock Market LLC (Nasdaq) onRHEA-AIneutral
09/26/22 8:00 AMNasdaq : SONN managementlow floatSonnet BioTherapeutics Appoints Ms. Lori McNeill to the Board of Directors and Formalizes the Company's Business Advisory CommitteeMs. McNeill is a former executive of Pfizer and an entrepreneur with expertise in marketing and public relations; she will sit on the Board of Directors and serve as the Chairperson of Sonnet's newly formed Business Advisory Committee (BAC) The BAC will advise the company on businessRHEA-AIvery positive
09/21/22 8:00 AMNasdaq : SONN clinical triallow floatSonnet BioTherapeutics Announces Progress in Two Phase 1 Dose-Escalation Trials of SON-1010SonnetRHEA-AIvery positive